N-acetyllactosamine (lacNAC) reverts human TIL anergy ex vivo.

from Tumor Immunology Round Table · host pedro

Hello In this edition of the podcast I will discuss a paper published by Demotte and collaborators published this year in the journal Immunity "Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes" vol 28, pag 414 of April 2008. In this paper the authors show that LacNAC can compete for galectin-3 binding freeing TCR from TIL to colocalize with CD8 and allow the recovery of efector functional on ex vivo freshly isolated TIL from ovarian cancer and gastric cancer. See you next time.

Episode metadata supplied by the publisher feed · Published Apr 20, 2008

Embed this episode

Attribution link and audio player

NOW PLAYING

N-acetyllactosamine (lacNAC) reverts human TIL anergy ex vivo.

0:00 32:24

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Tumor Immunology Round Table?

This episode is 32 minutes long.

When was this Tumor Immunology Round Table episode published?

This episode was published on April 20, 2008.

Can I download this Tumor Immunology Round Table episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!